A Catalyst-penned article on Trump’s deregulatory agenda has earned a [...]
About CatalystAdminThis author has not yet filled in any details.
So far CatalystAdmin has created 113 blog entries.
Join us on Jan. 9 as Catalyst President Nancy Bradish [...]
By Nancy Bradish Myers Yahooooo! What a thrill it is [...]
Pharmaceutical Online- What do Commissioner Gottlieb’s recent statements on orphan [...]
Gene Therapy Milestones: Gilead’s Acquisition of Kite Pharma and FDA’s Novartis CAR-T Approval Signal an Advancing Gene Therapy Field; What Are Key Takeaways for Gene Therapy Companies?
By Nancy Bradish Myers, Anne McNickle and Jill Hartzler Warner [...]
The Changing Regulatory Landscape Under Gottlieb and Trump: Catalyst Featured as Part of Expert Panel Webinar Series
Catalyst VP-Regulatory Policy and ex-FDAer Jill Hartzler Warner, JD, will [...]
By Nancy Bradish Myers At the DIA annual meeting earlier [...]
By Nancy Bradish Myers The DIA annual meeting session “Regulatory [...]
Promoting Drug Competition: What Both Innovator and Generic Companies Need to Know About FDA’s Emerging Competition Agenda
FDA is receiving “encouragement” from many directions right now to [...]
FDA User Fees, Drug Competition and Drug Pricing: Catalyst to Present on Regulatory and Legislative Vehicles for Change
On June 13, Catalyst President Nancy Bradish Myers will present [...]